Insider Transaction Report

Matthew E. Ros, Chief Operating Officer of Jasper Therapeutics, Inc. (JSPR), acquired 881 shares of Non-Voting Convertible Preferred Stock on July 20, 2026, through a private placement. This transaction, part of a securities purchase agreement with accredited investors, closed on July 20, 2026. The preferred stock is convertible into 61 shares of common stock per share, subject to beneficial ownership limitations (4.9% to 19.9%). The preferred stock has no expiration date. The acquisition was made under footnote F1 and F2, indicating the terms of the private placement and conversion rights.